Skip to main content
. 2018 Aug 8;12:226. doi: 10.3389/fncel.2018.00226

Figure 1.

Figure 1

Clinical development of microtubule stabilizing agents for Alzheimer's and Parkinson's disease, schizophrenia and cancer. Microtubule stabilizing agent grouping is according to pre-clinical, or clinical phases. Drugs developed for cancer are in gray; those for Alzheimer's and Parkinson's diseases are coded orange and pink respectively, and those under development for treatment of schizophrenia are in dark purple. We denote blood brain barrier (BBB) penetrance with upright triangles and non-penetrant drugs with an upside down triangle.